Calithera_Logo_Primary_RGB_M01.jpg
Bristol-Myers Squibb and Calithera Biosciences Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with CB-839 in Clear Cell Renal Cell Carcinoma
December 21, 2016 06:59 ET | Calithera Biosciences, Inc.
NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 21, 2016 (GLOBE NEWSWIRE) -- Bristol-Myers Squibb Company (NYSE:BMY) and Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences Announces Key Management Changes
December 12, 2016 07:00 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences to Host Conference Call and Webcast to Review Data Presented at the San Antonio Breast Cancer Symposium and EORTC-NCI-AACR Symposium
December 09, 2016 07:00 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 09, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences Reports CB-839 Phase I Triple Negative Breast Cancer Combination Data at the 2016 San Antonio Breast Cancer Symposium
December 06, 2016 09:00 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences Announces CB-839 Preclinical Data Selected for Presentation at the 58th American Society of Hematology Annual Meeting
December 02, 2016 07:01 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the discovering and developing novel...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences Reports CB-839 Phase I Renal Cell Carcinoma Combination Data at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
November 29, 2016 18:01 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 29, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on the development of novel cancer...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences Announces Four Abstracts Selected for Presentation at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting
November 11, 2016 07:00 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical stage biotechnology company focused on discovering and developing novel small...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences Reports Third Quarter 2016 Financial Results and Recent Highlights, and Raises Year-end Cash Guidance
November 09, 2016 16:06 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences to Report Third Quarter 2016 Financial Results on Wednesday, November 9, 2016
November 02, 2016 08:00 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...
Calithera_Logo_Primary_RGB_M01.jpg
Calithera Biosciences to Present at the Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology Roundtable
September 22, 2016 09:00 ET | Calithera Biosciences, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small...